KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aquestive Therapeutics (AQST) Gross Profit (2017 - 2025)

Historic Gross Profit for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $8.3 million.

  • Aquestive Therapeutics' Gross Profit fell 883.03% to $8.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.4 million, marking a year-over-year decrease of 17586.23%. This contributed to the annual value of -$16.9 million for FY2024, which is 15668.19% down from last year.
  • As of Q3 2025, Aquestive Therapeutics' Gross Profit stood at $8.3 million, which was down 883.03% from $5.4 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Gross Profit high stood at $15.6 million for Q2 2024, and its period low was -$49.2 million during Q4 2024.
  • In the last 5 years, Aquestive Therapeutics' Gross Profit had a median value of $6.8 million in 2022 and averaged $3.9 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Gross Profit skyrocketed by 76956.95% in 2021 and then tumbled by 73705.33% in 2024.
  • Aquestive Therapeutics' Gross Profit (Quarter) stood at $7.7 million in 2021, then crashed by 30.28% to $5.4 million in 2022, then surged by 43.65% to $7.7 million in 2023, then crashed by 737.05% to -$49.2 million in 2024, then skyrocketed by 116.87% to $8.3 million in 2025.
  • Its last three reported values are $8.3 million in Q3 2025, $5.4 million for Q2 2025, and $5.1 million during Q1 2025.